Lincoln Pharmaceuticals

Lincoln Pharmaceuticals reported net profit of Rs 27.70 crore for the April-June quarter, marking a 17% increase from Rs 23.69 crore in the same period last year. Total income grew 7.3% to Rs 169.34 crore compared to Rs 157.69 crore in the previous year. EBITDA rose 17.92% to Rs 39.08 crore from Rs 33.14 crore year-on-year. The company targets Rs 1,000 crore revenue within three years through business expansion into high-value product lines and new markets, aiming for 15-18% annual growth driven by cardiac, diabetic, dermatology, and ENT segments. During the quarter, the company launched its bulk drug manufacturing plant with Rs 4 crore investment from internal funds and received approvals for 10 products. Company shares surged 8.47% to close at Rs 576.90 on BSE.

Lincoln Pharmaceuticals Limited's Board of Directors approved the re-appointment of four senior executives for five-year terms, subject to shareholder approval at the upcoming Annual General Meeting. Mahendra G. Patel was re-appointed as Managing Director from October 1, 2025 to September 30, 2030. Three Whole Time Directors were also re-appointed: Hashmukh I. Patel for the same October 2025 to September 2030 period, while Ashish R. Patel and Munjal M. Patel will serve from November 14, 2025 to November 13, 2030. The appointments were recommended by the Nomination and Remuneration Committee. Mahendra G. Patel, a law graduate with over 45 years of pharmaceutical industry experience, has served as Managing Director since the company's incorporation and is a company promoter. Hashmukh I. Patel, a science graduate with three decades of pharma experience, manages domestic marketing and sales distribution. Ashish R. Patel holds an MBA in Marketing from the UK and handles marketing operations and sales strategies. Munjal M. Patel has a Master's degree in Finance from the USA with over 10 years of pharma experience and manages international trade and financial matters.

Lincoln Pharma reported Q1 EBITDA of 391 million rupees, representing an increase from 331 million rupees in the same period last year. The company's EBITDA margin improved to 25.38% compared to 22.54% year-over-year, indicating enhanced profitability and operational efficiency.